Literature DB >> 27277177

Determinants of plasma brain natriuretic peptide levels in untreated hypertensive patients.

Akiko Goda1, Shinji Nakao2, Takeshi Tsujino2, Masao Yuba2, Misato Otsuka2, Mika Matsumoto2, Chikako Yoshida2, Yoshiro Naito2, Masaaki Lee-Kawabata2, Mitsumasa Ohyanagi3, Tohru Masuyama2.   

Abstract

BACKGROUND: Plasma brain natriuretic peptide (BNP) level is elevated in patients with left ventricular (LV) hypertrophy reflecting not only altered LV geometry but LV systolic and/or diastolic dysfunction. However, the values and limitations of BNP measurements are unclear in patients with untreated hypertension. In this study, plasma BNP level was compared with LV geometric and functional characteristics in patients with untreated hypertension.
METHODS: Plasma BNP level was measured in 115 patients with untreated hypertension (72 males, 43 females, aged 60 ± 12 years). Routine echo parameters of LV geometry and LV systolic and diastolic performance were also determined.
RESULTS: LV ejection fraction was 67 ± 6% and plasma BNP level was 32 ± 30 pg/ml. Plasma BNP levels correlated with age, LV mass index (LVMI), and mitral E velocity, respectively (r = 0.46, p < 0.05; r = 0.21, p < 0.05; r = 0.29, p < 0.05, respectively), but not with systolic blood pressure or relative wall thickness (r = 0.01; r = -0.02). Plasma BNP level correlated with E/E' ratio (r = 0.27, p < 0.05, n = 77). When a stepwise multivariate analysis was performed, E velocity was selected in addition to age and LVMI as significant correlates of plasma BNP level.
CONCLUSIONS: LVMI and E velocity were independent determinants of plasma BNP level in patients with untreated hypertension. Plasma BNP level is substantially useful for the screening of abnormalities of LV geometry and/or function in patients with untreated hypertension. Additional echocardiography is useful to assess the mechanism of the elevation of plasma BNP level in untreated hypertensive patients.

Entities:  

Keywords:  BNP; Echocardiography; Hypertension; Hypertrophy; LV diastolic function

Year:  2011        PMID: 27277177     DOI: 10.1007/s12574-011-0086-9

Source DB:  PubMed          Journal:  J Echocardiogr        ISSN: 1349-0222


  14 in total

1.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

2.  Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy.

Authors:  L E Teichholz; T Kreulen; M V Herman; R Gorlin
Journal:  Am J Cardiol       Date:  1976-01       Impact factor: 2.778

3.  Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.

Authors:  D J Sahn; A DeMaria; J Kisslo; A Weyman
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

Review 4.  Measurement of cardiac output by M-mode and two-dimensional echocardiography: application to patients with hypertension.

Authors:  D C Wallerson; A Ganau; M J Roman; R B Devereux
Journal:  Eur Heart J       Date:  1990-12       Impact factor: 29.983

5.  Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension.

Authors:  T Nishikimi; F Yoshihara; A Morimoto; K Ishikawa; T Ishimitsu; Y Saito; K Kangawa; H Matsuo; T Omae; H Matsuoka
Journal:  Hypertension       Date:  1996-07       Impact factor: 10.190

6.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

7.  Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension.

Authors:  Y Shigematsu; M Hamada; M Mukai; H Matsuoka; T Sumimoto; K Hiwada
Journal:  J Hypertens       Date:  1995-01       Impact factor: 4.844

8.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.

Authors:  M R Cowie; A D Struthers; D A Wood; A J Coats; S G Thompson; P A Poole-Wilson; G C Sutton
Journal:  Lancet       Date:  1997-11-08       Impact factor: 79.321

9.  Brain natriuretic peptide as a cardiac hormone in essential hypertension.

Authors:  M Kohno; T Horio; K Yokokawa; K Murakawa; K Yasunari; K Akioka; A Tahara; I Toda; K Takeuchi; N Kurihara
Journal:  Am J Med       Date:  1992-01       Impact factor: 4.965

10.  Characterization of left ventricular filling abnormalities and its relation to elevated plasma brain natriuretic peptide level in acute to chronic diastolic heart failure.

Authors:  Shinji Nakao; Akiko Goda; Masao Yuba; Misato Otsuka; Mika Matsumoto; Chikako Yoshida; Mitsumasa Ohyanagi; Yoshiro Naito; Masaaki Lee; Takeshi Tsujino; Tohru Masuyama
Journal:  Circ J       Date:  2007-09       Impact factor: 2.993

View more
  2 in total

1.  Doxorubicin Cardiotoxicity and Cardiac Function Improvement After Stem Cell Therapy Diagnosed by Strain Echocardiography.

Authors:  Maira S Oliveira; Marcos B Melo; Juliana L Carvalho; Isabela M Melo; Mario Sl Lavor; Dawidson A Gomes; Alfredo M de Goes; Marilia M Melo
Journal:  J Cancer Sci Ther       Date:  2013

2.  Lower B-type natriuretic peptide levels predict left ventricular concentric remodelling and insulin resistance.

Authors:  Chisato Okamoto; Osamu Tsukamoto; Takuya Hasegawa; Tatsuro Hitsumoto; Ken Matsuoka; Seiji Takashima; Makoto Amaki; Hideaki Kanzaki; Chisato Izumi; Shin Ito; Masafumi Kitakaze
Journal:  ESC Heart Fail       Date:  2021-11-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.